There are currently 11 ongoing clinical trials involving Osteogenesis Imperfecta
Of the 11 trials,4 trials are in Phase I
Furthermore, 2 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Osteogenesis Imperfecta, a genetic disorder. The largest number of ongoing clinical trials for Osteogenesis Imperfecta is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Osteogenesis Imperfecta-related drug trials.
Amgen Inc: The leading ongoing Osteogenesis Imperfecta related clinical trial sponsor
Amgen Inc is the top sponsor for Osteogenesis Imperfecta-related ongoing clinical trials.
Department of Biotechnology India, Christian Medical College Vellore, Kobe University Hospital, and Keros Therapeutics Inc are among other notable clinical trial sponsors involved in Osteogenesis Imperfecta. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Osteogenesis Imperfecta
Neridronic acid (Nerixia) and Pamidronate disodium (Aredia) are among the key marketed drugs involving Osteogenesis Imperfecta.
Pamidronate disodium (Aredia) belongs to a group of chemical compounds known as bisphosphonates. It functions via Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1) Inhibitor mechanism of action. It is formulated as injectable lyophilized powder for solution and injectable solution for intravenous route of administration. Aredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Aredia used for the treatment of Paget’s Disease, osteogenesis imperfect, and also for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy. Aredia was first approved in 1990 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Novartis AG and its subsidiaries.
Neridronic acid (Nerixia) belongs to the class of bisphosphonate. It functions via Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1) Inhibitor mechanism of action. It is formulated as injection solution for intravenous route of administration as a solution concentrate. Nerixia is indicated for the treatment of imperfect osteogenesis, paget's bone disease and complex regional pain syndrome. Nerixia was first approved in 2002 and is marketed in Italy by Abiogen Pharma SpA.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward